Stratagene and Takara Settle PCR Suits

Shiga, Japan,: La Jolla, CA-Takara Bioand Stratagene have settled their patent disputes regarding enzyme blendsused in PCR technology. Financial details were unavailable. “We believe that there are a number of competitors selling products that are covered under our patent portfolio. It is our intention to make limited licenses available and recognize resulting licensing revenue,” stated Strategene President and CEO Joseph A. Sorge, MD.

< | >